Targeting COX-2 expression by natural compounds: A promising alternative strategy to synthetic COX-2 inhibitors for cancer chemoprevention and therapy

Cerella, Claudia; Sobolewski, Cyril; Dicato, Mario; Diederich, Marc

doi:10.1016/j.bcp.2010.06.050

Cited by 106 publications

(68 citation statements)

References 136 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cancer prevention remains an attractive strategy since the introduction of cancer chemoprevention by Sporn (2) and Wattenberg and colleagues (3). Among the various chemopreventing agents, COX-2-selective inhibitors were the most promising candidates due to their efficiency in cancer prevention and low toxicity (4)(5)(6). However, prolong administration of some COX-2-selective inhibitors was found to be associated with a significant increase in cardiovascular events (7,8), which resulted in the withdrawn of Vioxx from the market, followed by Bextra (valdecoxib).…”

Section: Introductionmentioning

confidence: 99%

Lactobacillus Salivarius REN Inhibits Rat Oral Cancer Induced by 4-Nitroquioline 1-Oxide

Zhang

Wang

Jiang

et al. 2013

Cancer Prevention Research

View full text Add to dashboard Cite

Despite significant advances in cancer therapy, cancer-related mobility and mortality are still rising. Alternative strategies such as cancer prevention thus become essential. Probiotics represent an emerging option for cancer prevention, but studies are limited to colon cancers. The efficiency of probiotics in the prevention of other cancers and the correlative mechanism remains to be explored. A novel probiotics Lactobacillus salivarius REN (L. salivarius REN) was isolated from centenarians at Bama of China, which showed highly potent antigenotoxicity in an initial assay. 4-nitroquioline 1-oxide (4NQO)-induced oral cancer model was introduced to study the anticancer activity of L. salivarius REN in vivo. The results indicated that oral administration of probiotic L. salivarius REN or its secretions could effectively suppress 4NQO-induced oral carcinogenesis in the initial and postinitial stage, and the inhibition was in a dose-dependent manner. A significant decrease of neoplasm incidence (65%-0%) was detected in rats fed with the high dose of L. salivarius REN [5 Â 10 10 CFU/kg body weight (bw)/d]. In vivo evidences indicated that the probiotics inhibited 4NQO-induced oral cancer by protecting DNA against oxidative damage and downregulating COX-2 expression. L. salivarius REN treatment significantly decreased the expression of proliferating cell nuclear antigen (PCNA) and induced apoptosis in a dose-dependent manner. Our findings suggest that probiotics may act as potential agents for oral cancer prevention. This is the first report showing the inhibitory effect of the probiotics on oral carcinogenesis. Cancer Prev Res; 6(7); 686-94. Ó2013 AACR.

show abstract

Section: Introductionmentioning

confidence: 99%

Lactobacillus Salivarius REN Inhibits Rat Oral Cancer Induced by 4-Nitroquioline 1-Oxide

Zhang

Wang

Jiang

et al. 2013

Cancer Prevention Research

View full text Add to dashboard Cite

show abstract

“…The importance of COX-2 inhibitors in cancer treatment has been previously demonstrated (6,7,18,19). There are two well-known inhibitors, NS398 and celecoxib, that have been investigated in various cancer models, including drugresistant cancer cells, as potential cancer treatments (11,12,14).…”

Section: Discussionmentioning

confidence: 99%

“…Cyclooxygenase-2 (COX-2) is an enzyme whose expression increases in response to inflammation and mitotic stimuli (6)(7)(8). COX-2 expression is also positively correlated with cancer cell proliferation and growth (9).…”

mentioning

confidence: 99%

Co-treatment with Celecoxib or NS398 Strongly Sensitizes Resistant Cancer Cells to Antimitotic Drugs Independent of P-gp Inhibition

Lim

Park

Lee

et al. 2016

View full text Add to dashboard Cite

Abstract. Background Antimitotic drugs are widely used to treat numerous types of cancers (1, 2). These compounds inhibit mitosis by targeting microtubules and preventing their polymerization or depolymerization (1-4). However, patients develop resistance to these drugs (5). Thus, to improve the efficacy of treatment, research has been focused on increasing antimitotic drug-associated apoptosis.Cyclooxygenase-2 (COX-2) is an enzyme whose expression increases in response to inflammation and mitotic stimuli (6-8). COX-2 expression is also positively correlated with cancer cell proliferation and growth (9). Increased COX-2 expression is also observed in P-glycoprotein (P-gp)-mediated drug resistance (10, 11). There are reports that the COX-2 inhibitors NS398 and celecoxib can suppress cancer by COX-2-dependent and COX-2-independent mechanisms (12, 13). In addition, co-treatment with COX-2 inhibitors showed increased sensitization to anti-cancer drugs in various models (14-17). Adverse effects, such as cardiovascular events, have been reported in clinical trials involving celecoxib-treated cancer patients (18,19). Better understanding of the mechanism governing the sensitization effect of COX-2 inhibitors in cancer patients could facilitate their safe therapeutic use.In the present study, we compared the sensitization efficacy of two well-known COX-2 inhibitors, NS398 and celecoxib, in antimitotic drug-resistant KBV20C cancer cells. We also tested whether co-treatment with COX-2 inhibitors increases sensitization in antimitotic drug-treated KBV20C resistant cancer cells. Since we have already demonstrated their strong inhibitory effects in drug-resistant cancer, the current study supports the use of COX-2 inhibitors in combinatorial treatment of antimitotic drug-resistant patients. Materials and MethodsReagents. Paclitaxcel (PAC) and verapamil (VER) were purchased from Sigma-Aldrich (St.Louis, MO, USA). Vinblastine (VIB) and vincristine (VIC) were purchased from Enzo Life Sciences (Farmingdale, NY, USA). Celecoxib and rhodamine123 (rhodamine) was purchased from Santa Cruz Biotechnology (Dallas, TX, USA). 5063

show abstract

“…It has been confi rmed that anti-infl ammatory drugs such as sulindac have not only a certain degree of anti-cancer effects, but also can prevent the incidence of colorectal cancer, lung cancer and other tumors in high-risk populations to some degree and may cooperate with current anti-cancer drugs [26][27][28][29][30][31]. It has been reported anti-infl ammatory plant natural products, such as resveratrol, genistein, quecetin, shikonin and epigallocatechin gallate, have been found to have anti-cancer potential [32][33].…”

Section: Cancer Inflammation and Traditional Chinese Medicinementioning

confidence: 99%

Inflammation, macrophage in cancer progression and chinese herbal treatment

Deng

Shen

et al. 2012

J Basic Clin Pharma

View full text Add to dashboard Cite

Targeting COX-2 expression by natural compounds: A promising alternative strategy to synthetic COX-2 inhibitors for cancer chemoprevention and therapy

Cited by 106 publications

References 136 publications

Lactobacillus Salivarius REN Inhibits Rat Oral Cancer Induced by 4-Nitroquioline 1-Oxide

Lactobacillus Salivarius REN Inhibits Rat Oral Cancer Induced by 4-Nitroquioline 1-Oxide

Co-treatment with Celecoxib or NS398 Strongly Sensitizes Resistant Cancer Cells to Antimitotic Drugs Independent of P-gp Inhibition

Inflammation, macrophage in cancer progression and chinese herbal treatment

Contact Info

Product

Resources

About